New insights on mucormycosis and its association with the COVID-19 pandemic
COVID-19 continues to cause significant fatality worldwide. Glucocorticoids prove to play essential roles in COVID-19 management; however, the extensive use of steroids together with the virus immune dysregulation may increase the danger of secondary infections with mucormycosis, an angioinvasive fu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-02-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.future-science.com/doi/10.2144/fsoa-2021-0122 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153140669644800 |
|---|---|
| author | Mona G Alshahawey Ghadir S El-Housseiny Noha S Elsayed Mohammad Y Alshahrani Lamia M EL Wakeel Khaled M Aboshanab |
| author_facet | Mona G Alshahawey Ghadir S El-Housseiny Noha S Elsayed Mohammad Y Alshahrani Lamia M EL Wakeel Khaled M Aboshanab |
| author_sort | Mona G Alshahawey |
| collection | DOAJ |
| description | COVID-19 continues to cause significant fatality worldwide. Glucocorticoids prove to play essential roles in COVID-19 management; however, the extensive use of steroids together with the virus immune dysregulation may increase the danger of secondary infections with mucormycosis, an angioinvasive fungal infection. Unfortunately, a definite correlation between COVID-19 and elevated mucormycosis infection cases is now clear worldwide. In this review, we discuss the historical record and epidemiology of mucormycosis as well as pathogenesis and associated host immune response, risk factors, clinical presentation, diagnosis and treatment. Special emphasis is given to its association with the current COVID-19 pandemic, including latest updates on COVID-19-associated mucormycosis cases globally, with recommendations for efficacious management. |
| format | Article |
| id | doaj-art-02677d7190104f84b898f6ccf759ea7f |
| institution | OA Journals |
| issn | 2056-5623 |
| language | English |
| publishDate | 2022-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-02677d7190104f84b898f6ccf759ea7f2025-08-20T02:25:48ZengTaylor & Francis GroupFuture Science OA2056-56232022-02-018210.2144/fsoa-2021-0122New insights on mucormycosis and its association with the COVID-19 pandemicMona G Alshahawey0Ghadir S El-Housseiny1Noha S Elsayed2Mohammad Y Alshahrani3Lamia M EL Wakeel4Khaled M Aboshanab51Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt2Department of Microbiology & Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt2Department of Microbiology & Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt3Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, 9088, Saudi Arabia1Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt2Department of Microbiology & Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, EgyptCOVID-19 continues to cause significant fatality worldwide. Glucocorticoids prove to play essential roles in COVID-19 management; however, the extensive use of steroids together with the virus immune dysregulation may increase the danger of secondary infections with mucormycosis, an angioinvasive fungal infection. Unfortunately, a definite correlation between COVID-19 and elevated mucormycosis infection cases is now clear worldwide. In this review, we discuss the historical record and epidemiology of mucormycosis as well as pathogenesis and associated host immune response, risk factors, clinical presentation, diagnosis and treatment. Special emphasis is given to its association with the current COVID-19 pandemic, including latest updates on COVID-19-associated mucormycosis cases globally, with recommendations for efficacious management.https://www.future-science.com/doi/10.2144/fsoa-2021-0122COVID-19epidemiologyfungal infectionhost immune responsemucormycosis |
| spellingShingle | Mona G Alshahawey Ghadir S El-Housseiny Noha S Elsayed Mohammad Y Alshahrani Lamia M EL Wakeel Khaled M Aboshanab New insights on mucormycosis and its association with the COVID-19 pandemic Future Science OA COVID-19 epidemiology fungal infection host immune response mucormycosis |
| title | New insights on mucormycosis and its association with the COVID-19 pandemic |
| title_full | New insights on mucormycosis and its association with the COVID-19 pandemic |
| title_fullStr | New insights on mucormycosis and its association with the COVID-19 pandemic |
| title_full_unstemmed | New insights on mucormycosis and its association with the COVID-19 pandemic |
| title_short | New insights on mucormycosis and its association with the COVID-19 pandemic |
| title_sort | new insights on mucormycosis and its association with the covid 19 pandemic |
| topic | COVID-19 epidemiology fungal infection host immune response mucormycosis |
| url | https://www.future-science.com/doi/10.2144/fsoa-2021-0122 |
| work_keys_str_mv | AT monagalshahawey newinsightsonmucormycosisanditsassociationwiththecovid19pandemic AT ghadirselhousseiny newinsightsonmucormycosisanditsassociationwiththecovid19pandemic AT nohaselsayed newinsightsonmucormycosisanditsassociationwiththecovid19pandemic AT mohammadyalshahrani newinsightsonmucormycosisanditsassociationwiththecovid19pandemic AT lamiamelwakeel newinsightsonmucormycosisanditsassociationwiththecovid19pandemic AT khaledmaboshanab newinsightsonmucormycosisanditsassociationwiththecovid19pandemic |